BCDA
BioCardia, Inc.
Price Chart
Latest Quote
$0.95
+0.08 (+9.25%)
Current Price
| Previous Close | $0.87 |
| Open | $0.86 |
| Day High | $0.95 |
| Day Low | $0.83 |
| Volume | 470,582 |
Stock Information
| Shares Outstanding | 14.88M |
| Total Debt | $412K |
| Cash Equivalents | $951K |
| Net Income | $-7.78M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $14.10M |
| EPS (TTM) | $-0.85 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $9.33M |
| Income | $-7.78M |
| Book/sh | $-0.10 |
| Cash/sh | $0.06 |
| Employees | 17 |
Financial Ratios
| Quick Ratio | 0.35 |
| Current Ratio | 0.41 |
Returns & Margins
| ROA | -252.00% |
Ownership
| Insider Ownership | 22.96% |
| Institutional Ownership | 5.45% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.58 |
| P/B | -9.77 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $15.50 |
Technical Indicators
| SMA20 | $0.90 |
| SMA50 | $1.04 |
| SMA200 | $1.28 |
| RSI | 52.11 |
| ATR | 0.1450 |
| Shares Float | 8.76M |
| Short Float | 3.46% |
| Short Ratio | 0.96 |
| Volatility | 0.50 |
| Rel Volume | 0.06 |
Performance History
| Week | +17.28% |
| Month | +5.56% |
| Quarter | -22.76% |
| 6 Months | -26.92% |
| YTD | -25.20% |
| Year | -58.70% |
| 3 Years | -97.19% |
| 5 Years | -98.56% |
| 10 Years | -99.58% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $0.95 | 479,800 |
| 2026-06-16 | $0.87 | 433,200 |
| 2026-06-15 | $0.83 | 660,400 |
| 2026-06-12 | $0.88 | 1,123,400 |
| 2026-06-11 | $0.80 | 805,800 |
| 2026-06-10 | $0.81 | 1,421,300 |
| 2026-06-09 | $0.86 | 2,250,900 |
| 2026-06-08 | $0.92 | 5,819,100 |
| 2026-06-05 | $1.03 | 151,174,600 |
| 2026-06-04 | $0.92 | 43,000 |
| 2026-06-03 | $0.87 | 200,800 |
| 2026-06-02 | $0.90 | 81,300 |
| 2026-06-01 | $0.92 | 67,400 |
| 2026-05-29 | $0.93 | 101,100 |
| 2026-05-28 | $0.92 | 116,200 |
| 2026-05-27 | $0.90 | 52,600 |
| 2026-05-26 | $0.91 | 140,700 |
| 2026-05-22 | $0.96 | 65,300 |
| 2026-05-21 | $0.91 | 54,800 |
| 2026-05-20 | $0.92 | 127,200 |
| 2026-05-19 | $0.95 | 144,300 |
| 2026-05-18 | $0.90 | 291,800 |
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
đ° Latest News
Sector Update: Healthcare Stocks Higher Late Afternoon
MT Newswires âĸ 2026-06-05T19:49:02ZSector Update: Healthcare Stocks Gain Friday Afternoon
MT Newswires âĸ 2026-06-05T17:50:31ZTop Midday Gainers
MT Newswires âĸ 2026-06-05T17:29:03ZWhy Did BCDA Stock Surge More Than 50% Today?
Stocktwits âĸ 2026-06-05T16:25:13Z
BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA)
InvestorsHub âĸ 2026-06-05T14:31:17Z
BioCardia (BCDA) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-18T13:00:22Z
BioCardia, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-16T12:30:00Z
BioCardia Inc (BCDA) Q1 2026 Earnings Call Highlights: Breakthroughs in Cardiac Therapy and ...
GuruFocus.com âĸ 2026-05-16T05:00:19ZBioCardia, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-26T12:30:00Z
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ...
GuruFocus.com âĸ 2026-03-25T03:01:46Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $58,000 | $477,000 | $1,352,000 |
| Operating Revenue | $0 | $58,000 | $477,000 | $1,352,000 |
| Reconciled Cost Of Revenue | - | - | - | - |
| Cost Of Revenue | - | - | - | - |
| Expenses | ||||
| Total Expenses | $8,278,000 | $8,059,000 | $12,121,000 | $13,253,000 |
| Other Income Expense | $50,000 | $55,000 | $73,000 | $-6,000 |
| Other Non Operating Income Expenses | $50,000 | $55,000 | $73,000 | $-6,000 |
| Operating Expense | $8,278,000 | $8,059,000 | $12,121,000 | $13,253,000 |
| Interest Expense | - | - | - | - |
| Net Non Operating Interest Income Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,228,000 | $-7,946,000 | $-11,571,000 | $-11,907,000 |
| Normalized Income | $-8,228,000 | $-7,946,000 | $-11,571,000 | $-11,907,000 |
| Net Income From Continuing And Discontinued Operation | $-8,228,000 | $-7,946,000 | $-11,571,000 | $-11,907,000 |
| Total Operating Income As Reported | $-8,278,000 | $-8,001,000 | $-11,644,000 | $-11,901,000 |
| Net Income Common Stockholders | $-8,228,000 | $-7,946,000 | $-11,571,000 | $-11,907,000 |
| Net Income | $-8,228,000 | $-7,946,000 | $-11,571,000 | $-11,907,000 |
| Net Income Including Noncontrolling Interests | $-8,228,000 | $-7,946,000 | $-11,571,000 | $-11,907,000 |
| Net Income Continuous Operations | $-8,228,000 | $-7,946,000 | $-11,571,000 | $-11,907,000 |
| Pretax Income | $-8,228,000 | $-7,946,000 | $-11,571,000 | $-11,907,000 |
| Operating Income | $-8,278,000 | $-8,001,000 | $-11,644,000 | $-11,901,000 |
| Net Interest Income | - | - | - | - |
| Interest Income | - | - | - | - |
| Special Income Charges | - | - | - | - |
| Interest Income Non Operating | - | - | - | - |
| Gross Profit | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-1.23 | $-2.90 | $-8.19 | $-10.05 |
| Basic EPS | $-1.23 | $-2.90 | $-8.19 | $-10.05 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-8,254,000 | $-7,934,000 | $-11,560,000 | $-11,819,000 |
| Reconciled Depreciation | $24,000 | $67,000 | $84,000 | $82,000 |
| EBITDA (Bullshit earnings) | $-8,254,000 | $-7,934,000 | $-11,560,000 | $-11,819,000 |
| EBIT | $-8,278,000 | $-8,001,000 | $-11,644,000 | $-11,901,000 |
| Diluted Average Shares | $6,666,943 | $2,743,828 | $1,411,998 | $1,181,398 |
| Basic Average Shares | $6,666,943 | $2,743,828 | $1,411,998 | $1,181,398 |
| Diluted NI Availto Com Stockholders | $-8,228,000 | $-7,946,000 | $-11,571,000 | $-11,907,000 |
| Research And Development | $4,962,000 | $4,387,000 | $7,726,000 | $8,834,000 |
| Selling General And Administration | $3,316,000 | $3,672,000 | $4,395,000 | $4,419,000 |
| Total Unusual Items | - | - | - | - |
| Total Unusual Items Excluding Goodwill | - | - | - | - |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $895,000 | $837,000 | $-1,603,000 | $4,892,000 |
| Total Assets | $3,413,000 | $3,724,000 | $2,987,000 | $9,793,000 |
| Total Non Current Assets | $681,000 | $1,102,000 | $1,527,000 | $1,928,000 |
| Other Non Current Assets | $171,000 | $171,000 | $171,000 | $171,000 |
| Current Assets | $2,732,000 | $2,622,000 | $1,461,000 | $7,864,000 |
| Prepaid Assets | $216,000 | $251,000 | - | - |
| Receivables | $20,000 | $0 | $63,000 | $201,000 |
| Accounts Receivable | $20,000 | $0 | $63,000 | $201,000 |
| Allowance For Doubtful Accounts Receivable | $0 | $0 | $-34,000 | $-11,000 |
| Gross Accounts Receivable | $20,000 | $0 | $97,000 | $212,000 |
| Cash Cash Equivalents And Short Term Investments | $2,496,000 | $2,371,000 | $1,103,000 | $7,363,000 |
| Cash And Cash Equivalents | $2,496,000 | $2,371,000 | $1,103,000 | $7,363,000 |
| Cash Financial | $2,496,000 | $2,369,000 | $1,101,000 | $470,000 |
| Other Current Assets | - | $251,000 | $295,000 | $300,000 |
| Cash Equivalents | - | $2,000 | $2,000 | $6,893,000 |
| Debt | ||||
| Total Debt | $528,000 | $951,000 | $1,315,000 | $1,631,000 |
| Long Term Debt And Capital Lease Obligation | $86,000 | $566,000 | $982,000 | $1,316,000 |
| Current Debt And Capital Lease Obligation | $442,000 | $385,000 | $333,000 | $315,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,518,000 | $2,887,000 | $4,590,000 | $4,901,000 |
| Total Non Current Liabilities Net Minority Interest | $86,000 | $566,000 | $982,000 | $1,316,000 |
| Current Liabilities | $2,432,000 | $2,321,000 | $3,608,000 | $3,585,000 |
| Current Deferred Liabilities | $535,000 | $532,000 | $561,000 | $965,000 |
| Payables And Accrued Expenses | $1,455,000 | $1,404,000 | $2,714,000 | $2,305,000 |
| Payables | $641,000 | $385,000 | $961,000 | $701,000 |
| Accounts Payable | $641,000 | $385,000 | $890,000 | $683,000 |
| Equity | ||||
| Common Stock Equity | $895,000 | $837,000 | $-1,603,000 | $4,892,000 |
| Total Equity Gross Minority Interest | $895,000 | $837,000 | $-1,603,000 | $4,892,000 |
| Stockholders Equity | $895,000 | $837,000 | $-1,603,000 | $4,892,000 |
| Retained Earnings | $-168,349,000 | $-160,121,000 | $-152,175,000 | $-140,604,000 |
| Other | ||||
| Ordinary Shares Number | $10,755,647 | $4,600,910 | $1,577,768 | $1,338,451 |
| Share Issued | $10,755,647 | $4,600,910 | $1,577,768 | $1,338,451 |
| Tangible Book Value | $895,000 | $837,000 | $-1,603,000 | $4,892,000 |
| Invested Capital | $895,000 | $837,000 | $-1,603,000 | $4,892,000 |
| Working Capital | $300,000 | $301,000 | $-2,147,000 | $4,279,000 |
| Capital Lease Obligations | $528,000 | $951,000 | $1,315,000 | $1,631,000 |
| Total Capitalization | $895,000 | $837,000 | $-1,603,000 | $4,892,000 |
| Additional Paid In Capital | $169,233,000 | $160,953,000 | $150,570,000 | $145,476,000 |
| Capital Stock | $11,000 | $5,000 | $2,000 | $20,000 |
| Common Stock | $11,000 | $5,000 | $2,000 | $20,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $86,000 | $566,000 | $982,000 | $1,316,000 |
| Current Deferred Revenue | $535,000 | $532,000 | $561,000 | $965,000 |
| Current Capital Lease Obligation | $442,000 | $385,000 | $333,000 | $315,000 |
| Current Accrued Expenses | $814,000 | $1,019,000 | $1,753,000 | $1,604,000 |
| Net PPE | $510,000 | $931,000 | $1,356,000 | $1,757,000 |
| Accumulated Depreciation | $-785,000 | $-761,000 | $-694,000 | $-619,000 |
| Gross PPE | $1,295,000 | $1,692,000 | $2,050,000 | $2,376,000 |
| Leases | $26,000 | $26,000 | $26,000 | $26,000 |
| Other Properties | $1,070,000 | $1,474,000 | $1,836,000 | $2,162,000 |
| Machinery Furniture Equipment | $199,000 | $192,000 | $188,000 | $188,000 |
| Properties | $0 | $0 | $0 | $0 |
| Dueto Related Parties Current | - | $0 | $71,000 | $18,000 |
| Construction In Progress | - | - | - | $0 |
| Buildings And Improvements | - | - | - | $1,588,000 |
| Duefrom Related Parties Current | - | - | - | - |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-7,443,000 | $-7,892,000 | $-9,986,000 | $-10,631,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-7,436,000 | $-7,886,000 | $-9,974,000 | $-10,561,000 |
| Cash Flow From Continuing Operating Activities | $-7,436,000 | $-7,886,000 | $-9,974,000 | $-10,561,000 |
| Operating Gains Losses | $481,000 | $482,000 | $331,000 | $295,000 |
| Investing Activities | ||||
| Capital Expenditure | $-7,000 | $-6,000 | $-12,000 | $-70,000 |
| Investing Cash Flow | $-7,000 | $-6,000 | $-12,000 | $-70,000 |
| Cash Flow From Continuing Investing Activities | $-7,000 | $-6,000 | $-12,000 | $-70,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $8,690,000 | $10,552,000 | $4,388,000 | $5,540,000 |
| Financing Cash Flow | $7,568,000 | $9,160,000 | $3,726,000 | $5,122,000 |
| Cash Flow From Continuing Financing Activities | $7,568,000 | $9,160,000 | $3,726,000 | $5,122,000 |
| Net Other Financing Charges | $-1,127,000 | $-1,392,000 | $-662,000 | $-418,000 |
| Net Common Stock Issuance | $8,690,000 | $10,552,000 | $4,388,000 | $5,540,000 |
| Common Stock Issuance | $8,690,000 | $10,552,000 | $4,388,000 | $5,540,000 |
| Other | ||||
| End Cash Position | $2,496,000 | $2,371,000 | $1,103,000 | $7,363,000 |
| Beginning Cash Position | $2,371,000 | $1,103,000 | $7,363,000 | $12,872,000 |
| Changes In Cash | $125,000 | $1,268,000 | $-6,260,000 | $-5,509,000 |
| Proceeds From Stock Option Exercised | $5,000 | $0 | - | $0 |
| Net PPE Purchase And Sale | $-7,000 | $-6,000 | $-12,000 | $-70,000 |
| Purchase Of PPE | $-7,000 | $-6,000 | $-12,000 | $-70,000 |
| Change In Working Capital | $-143,000 | $-1,196,000 | $129,000 | $-214,000 |
| Change In Other Current Liabilities | $-500,000 | $-483,000 | $-316,000 | $-237,000 |
| Change In Payables And Accrued Expense | $342,000 | $-854,000 | $666,000 | $420,000 |
| Change In Accrued Expense | $179,000 | $-538,000 | $482,000 | $416,000 |
| Change In Payable | $163,000 | $-316,000 | $184,000 | $4,000 |
| Change In Account Payable | $163,000 | $-316,000 | $184,000 | $4,000 |
| Change In Prepaid Assets | $35,000 | $44,000 | $5,000 | $163,000 |
| Change In Receivables | $-20,000 | $97,000 | $115,000 | $-54,000 |
| Changes In Account Receivables | $-20,000 | $97,000 | $115,000 | $-54,000 |
| Stock Based Compensation | $430,000 | $741,000 | $1,030,000 | $1,183,000 |
| Provisionand Write Offof Assets | $0 | $-34,000 | $23,000 | - |
| Depreciation Amortization Depletion | $24,000 | $67,000 | $84,000 | $82,000 |
| Depreciation And Amortization | $24,000 | $67,000 | $84,000 | $82,000 |
| Depreciation | $24,000 | $67,000 | $84,000 | $82,000 |
| Gain Loss On Sale Of PPE | $481,000 | $482,000 | $331,000 | $295,000 |
| Net Income From Continuing Operations | $-8,228,000 | $-7,946,000 | $-11,571,000 | $-11,907,000 |
| Change In Other Working Capital | - | - | $-341,000 | $-506,000 |
| Asset Impairment Charge | - | - | - | $295,000 |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Change In Other Current Assets | - | - | - | - |
| Change In Inventory | - | - | - | - |
Fetched: 2026-06-15